Recombinant Human HPRT Protein，His

HPRT (hypoxanthine-guanine phosphoribosyltransferase) is an essential enzyme in purine metabolism, catalyzing the conversion of hypoxanthine and guanine into their respective nucleotides, thereby playing a significant role in maintaining nucleotide pools within cells. Mutations in the HPRT gene lead to a range of clinical conditions, with Lesch-Nyhan syndrome being the most notable, characterized by neurological and behavioral symptoms alongside self-harming tendencies. HPRT deficiency results in an accumulation of uric acid and associated complications, highlighting the enzyme's critical function. Research into recombinant HPRT focuses on understanding its structure, function, and interactions at a molecular level, providing insights into its enzymatic mechanisms and potential therapeutic applications. By utilizing advanced techniques like X-ray crystallography and site-directed mutagenesis, scientists aim to elucidate the enzyme's active site and regulatory motifs, which could inform the development of novel treatments for conditions arising from HPRT deficiency. Additionally, recombinant HPRT production contributes to the exploration of gene therapy modalities, as restoring proper HPRT activity may ameliorate the biochemical abnormalities seen in affected individuals. The ongoing investigation into HPRT serves not only to address clinical manifestations of its deficiency but also to enhance the broader understanding of purine metabolism and its implications in various diseases.